Compare Neurocrine Biosciences Inc (NBIX) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco Solar ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Invesco Solar ETF trades at $43.75 (market cap $894.08M). The key difference: Neurocrine Biosciences Inc is far larger — about 16.1× Invesco Solar ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Invesco Solar ETF for 34 Days on average.
| NBIX | TAN | |
|---|---|---|
Market Cap | $14.36B | $894.08M |
Volume | 1,237,180 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $73.95 |
52-Week Low | $123.10 | $43.00 |
Typical Hold Time | 23 Days | 34 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
TAN (Invesco Solar ETF) trades at $43.75, up 0.51% with bearish technical signals from moving averages. The solar sector faces headwinds from high borrowing costs impacting project financing, as recent news highlights sector volatility. Technical indicators show 16 sell signals versus 1 buy, with key resistance at $44 and support at $43. The ETF's expense ratio of 0.7% is higher than broader energy alternatives, contributing to its underperformance versus the S&P 500 over five years.
Outlook remains cautious due to sector-specific risks including interest rate sensitivity and market saturation concerns. Investment opportunity exists for long-term renewable energy exposure, but risks include policy uncertainty, cost pressures, and competitive ETF alternatives with lower fees. The bearish technical setup suggests near-term pressure despite potential long-term energy transition tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
